Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + docetaxel + cisplatin + fluorouracil
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Cetuximab + docetaxel + cisplatin + fluorouracil is a multi-agent chemotherapy regimen used primarily for the treatment of locally advanced or recurrent/metastatic squamous cell carcinoma of the head and neck. This combination builds on the standard TPF regimen (docetaxel, cisplatin, and 5-fluorouracil) by adding cetuximab, an epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is a monoclonal antibody that blocks EGFR-mediated signaling pathways involved in tumor growth and survival. Docetaxel is a taxane that inhibits microtubule depolymerization, leading to cell cycle arrest; cisplatin forms DNA crosslinks causing apoptosis; and 5-fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis. The addition of cetuximab aims to enhance antitumor efficacy over standard chemotherapy regimens[1][2][5].
- Brand names
- Erbitux (for cetuximab)Taxotere (for docetaxel)Platinol (for cisplatin)Adrucil (for fluorouracil)
- Other names
- DPFCETPFTPF-C
02
Targets
Beyond the preview
Go deeper on cetuximab + docetaxel + cisplatin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + docetaxel + cisplatin + fluorouracil.